Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
NCT06747858
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Cystic Fibrosis
CFTR Gene Mutation
Interventions
BIOLOGICAL:
ARCT-032
Sponsor
Arcturus Therapeutics, Inc.